Chirfi Guindo Sells 10,000 Shares of Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the sale, the executive vice president owned 36,613 shares of the company’s stock, valued at $4,942,755. The trade was a 21.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Chirfi Guindo also recently made the following trade(s):

• On Thursday, August 6th, Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $135.78 on Friday. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.97. The company has a current ratio of 1.32, a quick ratio of 1.06 and a debt-to-equity ratio of 1.22. The company has a market capitalization of $334.98 billion, a price-to-earnings ratio of 108.62, a P/E/G ratio of 5.85 and a beta of 0.19. The stock’s fifty day simple moving average is $125.54 and its 200-day simple moving average is $119.94.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.Merck & Co., Inc.’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.5%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Wall Street Analysts Forecast Growth

Several analysts recently commented on MRK shares. BMO Capital Markets raised their price target on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. JPMorgan Chase & Co. increased their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. CICC Research started coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price for the company. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $135.50.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently made changes to their positions in MRK. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $25,000. Abound Financial LLC bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $26,000. High Note Wealth LLC lifted its stake in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new stake in Merck & Co., Inc. in the fourth quarter worth approximately $31,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.